| 1.07 -0.02 (-1.83%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.61 |
1-year : | 1.86 |
| Resists | First : | 1.37 |
Second : | 1.6 |
| Pivot price | 1.27 |
|||
| Supports | First : | 1.01 | Second : | 0.84 |
| MAs | MA(5) : | 1.11 |
MA(20) : | 1.31 |
| MA(100) : | 1.07  |
MA(250) : | 1.05 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 14.6 |
D(3) : | 16.1 |
| RSI | RSI(14): 32.4 |
|||
| 52-week | High : | 1.82 | Low : | 0.46 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ UNCY ] has closed above bottom band by 10.3%. Bollinger Bands are 42.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.13 - 1.14 | 1.14 - 1.15 |
| Low: | 1.03 - 1.04 | 1.04 - 1.05 |
| Close: | 1.06 - 1.07 | 1.07 - 1.08 |
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Wed, 10 Apr 2024
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference - GlobeNewswire
Thu, 28 Mar 2024
UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023 - InvestorPlace
Thu, 28 Mar 2024
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update - GlobeNewswire
Mon, 25 Mar 2024
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress - Yahoo Finance
Thu, 14 Mar 2024
Unicycive secures $50 million in private placement By Investing.com - Investing.com
Thu, 14 Mar 2024
Will Unicycive Therapeutics Inc (UNCY) Outperform the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 1.374e+007 (%) |
| Held by Institutions | 18.3 (%) |
| Shares Short | 35 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.077e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 77.6 % |
| Return on Equity (ttm) | -152.7 % |
| Qtrly Rev. Growth | 675000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -25.78 |
| Dividend | 0 |
| Forward Dividend | 256780 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|